Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

Drug (Brand / Generic)

Vosevi™ / Sofosbuvir/Velpatasvir/Voxilaprevir

Developer

Gilead Sciences

Therapy Class

Direct-acting antiviral (DAA)

Current Indication

Chronic hepatitis C virus (HCV) Infection

Market Sector

Anti-infective

Development Status

Approved in the US
Expand

Go Top